Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Anacor Purchase Marks Pfizer's Post-Allergan Bolt-On Strategy

Executive Summary

Celgene pays Agios $200m up front for collaboration in immuno-oncology. Biogen inks pacts with Regenxbio and Penn to apply AAV technology to its developing gene-therapy program.

You may also be interested in...



Keeping Track: Approvals For Pfizer's Eucrisa, Vericel's Maci; Submissions From Flexion, AcelRx, Ironshore

The latest drug development news and highlights from our FDA Performance Tracker.

Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole

Pfizer agreed to acquire Anacor for roughly $5.2bn, with the expectation that its late-stage PDE4 inhibitor crisaborole, under review by FDA for the treatment of atopic dermatitis, will generate peak sales of more than $2bn.

Spotlight Returns To Biogen R&D To Sustain Success

After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS057653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel